A Phase II Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Immunogenicity of an IM Influenza Vaccine (Multimeric-001) Followed by Administration of TIV to Elderly Volunteers.
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Influenza virus vaccine (Primary) ; Aluminium phosphate
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors BiondVax Pharmaceuticals
- 12 Jan 2017 Results presented at The Vaccine journal, as reported by a BiondVax Pharmaceuticals media release.
- 12 Jan 2017 Results published in a BiondVax Pharmaceuticals media release.
- 05 Jan 2017 Results published in the Vaccine.